ESET Research uncovers variants of AsyncRAT, popular choice of cybercriminals 
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease 
XDS Datacentres signs 15-year deal to host 10MW of AI workloads in Saudi’s Desert Dragons facilities Semtech Adds Semiconductor Industry Leader to Board of Directors
Technology Executive Hong Q. Hou Joins Semtech to Help Oversee Next Era of Growth CAMARILLO,…
Capital Flows to Solar Power During the Energy Transition, an Industrial Info News Alert
SUGAR LAND, Texas–(BUSINESS WIRE)–Researched by Industrial Info Resources — The energy transition is apparent in…
California Resources Corporation Schedules Second Quarter 2023 Earnings Conference Call
LONG BEACH, Calif.–(BUSINESS WIRE)–California Resources Corporation (NYSE: CRC) plans to release its second-quarter 2023 financial…
IOG Resources Announces Senior Management Promotions and Promotes Tommy Woolley to Chief Executive Officer
DALLAS–(BUSINESS WIRE)–IOG Resources Management (“IRM”), the management company responsible for managing IOG Resources, LLC (“IOGR…
What to Look for in a Modern Insider Risk Solution
Insider threat can be described as the potential of an employee to utilize their authorised…
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical…
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical…
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential…
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential…
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN,…
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN,…
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
Baudax Bio Acquires TeraImmune, Inc.
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an…
Baudax Bio Acquires TeraImmune, Inc.
TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an…
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
Financing represents minimum cash required to consummate the business combination and bridge AEON through key…
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
Financing represents minimum cash required to consummate the business combination and bridge AEON through key…
CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.
– Financing is expected to extend cash runway into the 2nd half of 2025 based…